cyrilzakka/clinical-trials huggingface dataset:
Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial

The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls.

The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls. (Tey et al.) With this dose fractionation is used for bleeding, there is an increase in response rates from 55%(historical) to 75%for pain, there is an increase in response rates from 25% (historical) to 45% for obstruction, there is an increase in response rates from 25% (historical) to 45%

Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven adenocarcinoma of the stomach
* Treated with palliative intent
* At least one index symptom such as bleeding, obstruction or pain
* No prior abdominal radiotherapy
* Not on chemotherapy

Exclusion Criteria:

* Patients treated with radical intent
* Previous abdominal radiotherapy
* Patients on chemotherapy
Sleep-disordered Breathing After Solid Organ Transplantation

Sleep-disordered breathing (SDB) describes a group of disorders in which partial or complete cessation of breathing occurs many times throughout the night, resulting in daytime sleepiness or fatigue that interferes with a person's ability to function and reduces quality of life. Transplantation has become an important treatment modality for end-stage organ failure. Transplant recipients are now living longer and, hence, develop chronic adverse medical conditions. Furthermore, transplantation is associated with weight gain. Despite the high prevalence of poor sleep and cardiovascular conditions among transplant patients, SDB is not well studied in these patients.

The primary research objective is to evaluate the prevalence, incidence and type (central or obstructive) of SDB in patients after lung transplantation.

Secondary research objectives are the evaluation of correlations between severity of SDB and clinical findings (weight, medical therapy, heart function, lung function, renal function, graft failure, ...). Furthermore, the investigators will evaluate the relationship between SDB and cardiovascular morbidity.

Eligibility Criteria:
Inclusion Criteria:

* Patients 1 year after lung transplantation

Exclusion Criteria:

* Refusal of PSG
* Medical contra-indication to perform PSG
Infusion of Apomorphine: Long-term Safety Study

This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

This Phase 3, multicenter, open-label study will assess the long-term safety and tolerability of continuous subcutaneous infusion of apomorphine in advanced Parkinson's disease (PD) patients whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

Further, this study will assess the clinical effectiveness of continuous apomorphine subcutaneous infusion in reducing "off" time in advanced PD patients and to assess the clinical effectiveness of continuous subcutaneous infusion of apomorphine in improving "on" time without resulting in an increase in troublesome dyskinesias.

Eligibility Criteria:
Inclusion Criteria:

* Advanced idiopathic PD consistent with UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria
* Overall motor control is unsatisfactory in the opinion of the Investigator and subject despite optimized treatment with available therapies, which must include a stable regimen of daily maintenance levodopa (or levodopa/carbidopa), and at least one of the following other classes of therapies:
* Dopamine agonists (note: APOKYN intermittent injection is not to be considered here)
* Monoamine oxidase B \[MAO B\] inhibitors
* Catechol-O-methyltransferase (COMT) inhibitors
* Deep brain stimulation (DBS)
* Levodopa/carbidopa intestinal gel surgery (Duopa, Duodopa)
* Other - amantadine at doses of up to 400 mg per day)
* Experiences "off" periods averaging ≥3.0 hours per waking day
* Other criteria will be discussed in detail with potential subjects by site Investigator

Exclusion Criteria:

* Planned surgical intervention for the treatment of Parkinson's disease during participation in the study
* History of hypersensitivity to apomorphine hydrochloride or any of the ingredients of APOKYN PFS, including sodium metabisulfite
* Known, suspected, or planned pregnancy or lactation.
* Recent history (within the previous 12 months) of alcohol or substance abuse
* History of impulsive/compulsive behaviors primarily associated with the use of dopamine agonists
* History of previously treated or current diagnosis of malignant melanoma
* Exhibits certain signs and symptoms of cardiovascular disease
* Other criteria will be discussed in detail with potential subjects by site Investigator
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study

COVID-19 is the infectious disease caused by the novel coronavirus known as SARS-CoV-2, that appeared in 2019. The World Health Organisation (WHO) declared the novel coronavirus a pandemic on 11 March 2020. The evolution of the pandemic is varying across countries, affected in part by different containment strategies ranging from extreme lockdown to relative inaction. As a result, there are regional waves of the disease and pockets of vulnerable populations. Globally, governments have acknowledged that effective vaccines against COVID-19 are the only way to guarantee a safe and sustained exit strategy from repeated lockdowns.

The objective of this study is to estimate the vaccine effectiveness against hospitalizations due to circulating COVID-19 VoC among subjects eligible for vaccination with the AstraZeneca or any other COVID-19 vaccine provided in their country as per national/regional immunization recommendations prior to hospital admission.

The study design is an observational prospective active-surveillance hospital-based study, with a test-negative case-control design (TNCC) of hospitalized COVID-19 like cases undergoing testing for SARS-CoV-2

LatInamerican Vaccine Effectiveness against hospitalizations due to circulating COVID-19 VoC RWE study is an observational prospective active-surveillance hospital-based study, with a test-negative case-control design (TNCC) of hospitalized COVID-19 like cases undergoing testing for SARS-CoV-2 by RT-PCR or rapid antigen test with the participation of countries from six LatAm Marketing Companies (Argentina, Brazil, Colombia, Costa Rica, Mexico and Panama).

This study will generate new information regarding vaccine effectiveness (VE) in the RW setting for populations where evidence is still unavailable

Eligibility Criteria:
Inclusion Criteria:

* 18y and older
* Ever eligible for vaccination with the AstraZeneca or any other COVID-19 vaccine provided in their country as per national/regional immunization recommendations prior to hospital admission.
* Hospitalization due to COVID-19 like case
* Willing and able to provide informed consent (or by legal accepted representative if patient are not able to provide their signature by themselves)

Exclusion Criteria:

* Cannot be swabbed or other conditions that contra-indicate swabbing
* COVID-19 hospitalization within 3 months prior to the current admission. Hospital transfers are not considered as a prior hospitalization.
Future Patient - Telerehabilitation of Heart Failure Patients

The idea behind the Future Patient research project is to develop a telerehabilitation program and tools for patients with heart failure.

The hypothesis for this study is that participation in a telerehabilitation program for patients with heart failure will increase the patients' quality of life and multi-parametric (subjective and objective) individualized monitoring in a telerehabilitation program for patients with heart failure will increase detection of worsening of symptoms and avoid future hospitalization of the HF-patients.

The overall aim is to test, implement and evaluate a telerehabilitation program for patients with heart failure from clinical, psychosocial, health literacy and e-health literacy, inter-organizational, health economic and technical perspectives.

Furthermore, this study has sub aims:

* To increase the quality of life for patients with Heart Failure (HF)
* To optimize the medical treatment of patients with HF
* To perform multi-parametric (subjective and objective) individualized monitoring in order to detect worsening of symptoms and avoid hospitalizations
* To increase physical activities for patients with heart failure in everyday life in a telerehabilitation program
* To facilitate patient-initiated self-care management actions upon the following early detection of changes in source data (steps taken, weight, blood pressure, pulse, sleep, illness perception, motivation, anxiety and depression)
* To evaluate patients health literacy and e-health literacy participating in a telerehabilitation program and rehabilitation program
* To test and evaluate the Heart Portal - a digital toolbox for improved self-management for patients with heart failure and their relatives
* To explore the experiences and perspectives of the patients and their relatives when being part of a telerehabilitation program
* To test and evaluate a cross sector communication platform from a patient and healthcare professional perspective
* To perform a cost-effectiveness analysis of total costs of healthcare and rehabilitation services

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with HF according to New York Heart Association (NYHA) Class I-IV with max 20 % in class I or who have a current hospitalization for acute decompensated HF within the past two weeks
* Adults (18 years or older); no upper age limit
* Patients living in Viborg and Skive Municipality
* Living at home and capable of caring for him/herself
* Have basic computer skills or a relative who have basic computer skills
* Informed consent to participate in a telerehabilitation program
* May have a pacemaker

Exclusion Criteria:

* Pregnancy
* Drug addiction defined as the use of cannabis, opioids or other drugs
* Previous neurologic, musculoskeletal or cognitive disability or active psychiatric history (as noted in the medical record) other than depression or anxiety related to cardiac or other chronic illness
* Lack of ability to cooperate
* Does not speak Danish
Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint

Osteoarthritis of the hip is a common type of osteoarthritis which can cause significant problems. First-line of management for patient with osteoarthritis consists of weight reduction, education, and analgesic medication. If necessary, invasive treatment like total hip replacement are performed for the patient. The objective of this study was to assess the safety of bone marrow mesenchymal stem cells (BM-MSCs) implantation in patients with hip osteoarthritis

This is a phase one clinical study designed to investigate the safety of intra-articular injection of cultured autologous BM-MSCs in patients with severe hip osteoarthritis candidate for total hip replacement. All subjects will undergo bone marrow aspiration. Autologous MSCs will be extracted and cultured for 4 weeks. Patients will receive intra-articular injection of cultured MSCs under the guide of fluoroscopy. Paraclinical studies (X-Ray and MRI) will be done before and 6 months after treatment. Pain relief and functional improvement of the joint will be assessed by VAS, WOMAC, and Harris Hip Score questionnaire before treatment, and 2 and 6 months after treatment.

Eligibility Criteria:
Inclusion Criteria:

* Osteoarthritis diagnosed by MRI
* End stage osteoarthritis candidate for total hip replacement

Exclusion Criteria:

* Pregnancy or lactating
* Positive tests for HIV, HCV, HBV
* Active neurologic disorder
* End organ damage
* Uncontrolled endocrine disorder
Second Trimester Pregnancy Termination With Foley Catheter

One of the methods used to induce second trimester pregnancy termination is the placement of a transcervical Foley catheter. The aim of this randomized controlled study was to assess in pregnant women with an unfavourable cervix, whether there is a difference in efficacy between the two most commonly used insufflation volumes of Foley catheter (30mL and 50mL).


Eligibility Criteria:
Inclusion Criteria:

* singleton pregnancies
* second trimester pregnancy ermination

Exclusion Criteria:

* multiple pregnancies
Acute Effects of Foam Rolling on Viscoelastic Tissue Properties and Fascial Sliding

Treatment or training of fascial tissues has moved into the focus of medical research in the last decade. In this context, the use of foam rollers or roller massagers for self-myofascial-release (SMR) techniques has become increasingly popular in health and fitness professionals. The primary objective of these techniques is to mimic manual massage or myofascial-release therapy with a self-usable tool. Recent studies suggest that SMR improves, inter alia, range of motion (ROM) without a decrease in neuromuscular performance (Cheatham et al. 2015).

Concurrent effects on the muscle and especially the surrounding connective tissue network have been proposed as underlying mechanisms for these observed changes in ROM after SMR. Several authors assume a positive effect of SMR on sliding properties of different independent fascial layers. Also, changes in passive tissue stiffness is suggested. Passive stiffness is thereby characterized by passive resistance in the tissues' (muscles') functional direction, the passive resistive torque (PRT).

In conclusion, for many of the proclaimed effects of SMR, such as improvements of sliding of fascial layers or decreases of passive stiffness, there is a lack of evidence in the literature. Therefore, the aim of the study is to evaluate acute effects of SMR on the viscoelastic properties of the muscles on the anterior thigh and the corresponding fascia.

In a cross over design, 16 subjects receive all of the following interventions after a familiarization session: a) 2x60 seconds of SMR at the anterior thigh, b) 2x60 seconds of static stretching at the anterior thigh, c) no intervention in a balanced permutated randomization sequence. Before and directly after each intervention, outcome parameters are collected.

Passive Resistive Torque is evaluated using a computerized isokinetic dynamometer. In passive mode, the lower leg is moved from full knee extension (0°) to the point of maximal knee flexion with a velocity of 5°/s. Torque and angle are recorded at 100 Hertz (Hz). Sliding of fascial layers is quantified with a frame-by-frame cross correlation algorithm of high-resolution ultrasound images (Dilley et al. 2001).

First stretch sensation is quantified using the passive mode in the isokinetic dynamometer.

Maximal ROM is detected using a an ultrasonographic movement analysis system in a prone position.


Eligibility Criteria:
Inclusion Criteria:

* Age between 20-40 years

Exclusion Criteria:

* History of orthopedic injuries in the lower extremity in the last 12 months
* Any history of psychiatric, cardiovascular, endocrine, neurological, or metabolic disorders
* Any current medication that might affect pain perception or proprioception
* Muscle soreness
* Pregnancy/nursing period
* Nonspecific musculoskeletal disorders
The Use of Karl Storz Curved Fetoscope (11508aak) and Its Straight Version (11506akk) for In-utero Surgery

The purpose of this study is to prospectively evaluate the efficacy of KARL STORZ curved fetoscope (11508AAK) and its straight version (11506AAK) for in-utero surgery

Outcome data will be compared to that of The Fetal Center's historical control group that underwent in-utero surgery without curved fetoscopes

Eligibility Criteria:
Inclusion Criteria:

* Pregnant woman
* The patient fulfills the criteria for in-utero surgery based on the standard of care, which is specific for each condition
* Patient of the baby provides signed informed consent that details the maternal and fetal risks involved with the procedure

Exclusion Criteria:

* Contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia
* Allergy or previous adverse reaction to a study medication specified in this protocol
* Preterm labor, preeclampsia, or a uterine anomaly (e.g., large fibroid tumor) that is unavoidable during surgery in the index pregnancy
* Fetal aneuploidy, genomic variants of known significance if an amniocentesis has been performed, other major fetal anomalies or disorders that may impact the fetal/neonatal survival, or a known syndromic mutation
* Suspicion of a major recognized syndrome by ultrasound or MRI
* Maternal BMI \>40 kg/m2
* High risk for fetal hemophilia
A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients

The goal of this behavioral research study is to look at the reasons that may prevent women from getting early treatment for their cervical cancer.

Little is known about what prevents women with cervical cancer from getting early and possibly curative treatment. This study consists of a series of questionnaires that ask questions about religion; coping; access to health care; physical, emotional, and spiritual well-being; understanding of health questions; control; fear; anxiety; and other health beliefs to determine why some women delay coming in for check-ups and why some women do not complete their treatments. It is thought that health beliefs influence behavior practices and that by identifying these issues, things can be done to improve the health condition and results for these patients.

You will be asked to complete a series of questionnaires at 2 specific time points: The first time point will be before treatment begins and the second time point will be within a month following completion of treatment.

Filling out the questionnaires should take about 45 minutes each time. You should have adequate time to complete these questionnaires during your clinic appointment.

If you want to take part but are too ill to complete the questionnaires, you will be provided a pre-addressed, stamped envelope, so that you can mail them back to the study staff at your earliest convenience.

This is an investigational study. This is an investigational study. Up to 150 patients will be enrolled at Lyndon B. Johnson General Hospital.

Eligibility Criteria:
Inclusion Criteria:

1) All newly diagnosed cervical cancer patients through Stage IVB presenting to the Lyndon B. Johnson General Hospital (LBJ) Gynecologic Oncology Clinic.

Exclusion Criteria:

1) Patients who are not English or Spanish speaking.
Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Individuals With Multiple Sclerosis

The aim of this study is to study the validity and reliability of Core Lower Urinary Tract Symptoms Score in patients with multiple sclerosis.

Multiple sclerosis is an autoimmune disease that can affect any part of the central nervous system. Multiple sclerosis, whose prevalence is increasing every year in the world, brings with it many symptoms. Lower urinary tract symptoms develop secondary to demyelinating lesions in the spinal cord and pontine micturition center in the disease pathophysiology commonly seen in Multiple sclerosis and other symptoms seen in Multiple sclerosis (inactivity, fear of movement, etc.). Due to the multifocal and widespread involvement of the CNS, Lower urinary tract symptoms in Multiple sclerosis patients are variable and their severity varies among Multiple sclerosis patients. Lower urinary tract symptoms are divided into 3 groups as storage, voiding and post-voiding symptoms. The rate of urinary complications in Multiple sclerosis patients is significantly higher compared to the general population. Although it is a common symptom in multiple sclerosis , the evaluation of Lower urinary tract symptoms in individuals with Multiple sclerosis is quite limited in the literature. Evaluation of Lower urinary tract symptoms seen in Multiple sclerosis with appropriate assessment tools is important to obtain comprehensive information about the progression of the disease. There are many questionnaires used in the evaluation of Lower urinary tract symptoms. While the International Prostate Symptom Score and the Danish Prostate Symptom Score, which are frequently used for benign prostatic hyperplasia, are used; Overactive Bladder Questionnaire-V8 was developed to evaluate overactive bladder symptoms. However, these questionnaires are also frequently used in the evaluation of Lower urinary tract symptoms. Since the purpose of developing the questionnaires is for different diseases, they are not comprehensive enough for Lower urinary tract symptoms. The Core Lower Urinary Tract Symptoms Score is a questionnaire developed to comprehensively evaluate lower urinary tract symptoms. Although the Core Lower Urinary Tract Symptoms Score Turkish validity and reliability study was conducted by Erbay et al. in 2022, its validity and reliability in Multiple sclerosis patients has not been performed.

Eligibility Criteria:
Inclusion Criteria:

* Being between 18-65 years old
* Being diagnosed with multiple sclerosis by a specialist
* Being willing to participate in the study
* Being literate

Exclusion Criteria:

* Not volunteering to participate in the study
* Having a neurological disorder that prevents speech
Newly Diagnosed Glioblastoma

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness


Eligibility Criteria:
Inclusion Criteria:

* Understood and Signed an informed consent form., with good compliance
* Age: 18-75 years old；.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2；Life expectancy of at least 3 months.
* Glioblastoma confirmed by histology ;
* Random time is 4-6 weeks from the last operation , and the investigator judges that the surgical wound has healed well;
* Within 5 days before administration, the dosage of corticosteroids was stable or gradually decreased;
* Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study ；Not Pregnant or breastfeeding women,Pregnancy before pregnancy screening, the women who blood / urine results were positivetherapy.

Exclusion Criteria:

* Have previously received systemic radiotherapy and chemotherapy for GBM;
* IDH1/2 mutations are present
* Contraindicated for MRI examination
* The tumor only occurs in the brain stem
* Radiologically obvious diffuse meningeal dissemination
* Imaging shows that the tumor has invaded the periphery of important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal hemorrhage, cerebrovascular malformations or other bleeding tendency during the subsequent study period;
* Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident , deep vein thrombosis and pulmonary embolism；
* Other malignant tumors have occurred or are currently present at the same time within 3 years.
* There are many factors that affect oral medications ;
* Received anti-tumor Chinese patent medicine which were approved by NMPA Within 2 weeks before the start of the study.
* A clear history of neurological or psychiatric diseases, moderate or higher epilepsy , moderate or higher aphasia or dementia
* Participated in other anti-tumor drug clinical trials within 4 weeks before grouping;
* Other conditions which are not fit for this study assessed by investigator.